9-amino-9-azabicyclo<3.3.1>nonane | 4390-44-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 9-amino-9-azabicyclo<3.3.1>nonane
• 英文别名: 9-Azabicyclo[3.3.1]nonan-9-amine
• CAS: 4390-44-7
• 化学式: C₈H₁₆N₂
• 分子量: 140.228
• InChiKey: GCHYKFXTHNUFAW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  苯酐 、 9-amino-9-azabicyclo<3.3.1>nonane 以 苯 为溶剂， 反应 10.0h， 以88%的产率得到2-(9-Aza-bicyclo[3.3.1]non-9-yl)-isoindole-1,3-dione
  参考文献：
  名称：

  One-electron oxidation of tetrasubstituted hydrazides and dihydrazides

  摘要：

  DOI：

  10.1021/ja00348a027

文献信息

• [EN] HEPATITIS B ANTIVIRAL AGENTS<br/>[FR] AGENTS ANTIVIRAUX DE L'HÉPATITE B
  申请人：ENANTA PHARM INC

  公开号：WO2020247561A1

  公开（公告）日：2020-12-10

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: Formula (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明揭示了化合物的化学式（I）或其药用可接受的盐：化学式（I），其抑制由乙型肝炎病毒（HBV）编码的蛋白质或干扰乙型肝炎病毒的生命周期的功能，并且也可用作抗病毒剂。本发明还涉及包含上述化合物的药物组合物，用于治疗患有HBV感染的受试者。该发明还涉及通过给受试者投予包含本发明化合物的药物组合物来治疗受试者的HBV感染的方法。
• Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
  申请人：ENANTA PHARMACEUTICALS, INC.

  公开号：US10457703B2

  公开（公告）日：2019-10-29

  The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.

  本发明提供了式 I 所代表的化合物或其药学上可接受的盐、立体异构体、溶液剂、水合物或其组合、 本发明还提供了包含这些化合物的药物组合物以及使用这些化合物治疗 FXR 介导或 TGR5 介导的疾病或病症的方法。
• Thermodynamic destabilization of N-centered radical cations by a .gamma.-keto group
  作者：Stephen F. Nelsen、Carl R. Kessel、Loretta A. Grezzo、Daniel J. Steffek

  DOI：10.1021/ja00537a010

  日期：1980.8
• BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF
  申请人：ENANTA PHARMACEUTICALS, INC.

  公开号：US20200109164A1

  公开（公告）日：2020-04-09

  The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.